Trending

Sarepta

Sarepta agree gene therapy R&D pact with Selecta

Sarepta agree gene therapy R&D pact with Selecta

Rare disease specialist Sarepta Therapeutics has joined with Selecta Biosciences in a research pact to develop ways to allow its gene therapies

X

Sarepta agree gene therapy R&D pact with Selecta

https://pharmaphorum.com/news/sarepta-forges-gene-therapy-rd-alliance-with-selecta/

Roche snaps up ex-US rights to Sarepta’s DMD gene therapy

Roche snaps up ex-US rights to Sarepta’s DMD gene therapy

Roche has bought ex-US rights to Sarepta’s Duchenne muscular dystrophy (DMD) gene therapy in a potential multi-billion dollar

X

Roche snaps up ex-US rights to Sarepta’s DMD gene therapy

https://pharmaphorum.com/news/roche-snaps-up-ex-us-rights-to-sareptas-dmd-gene-therapy/

Sarepta rebounds on data for limb-girdle muscular dystrophy gene therapy

Sarepta rebounds on data for limb-girdle muscular dystrophy gene therapy

Shares in Sarepta spiked on positive data for its gene therapy for a form of muscular dystrophy, after

X

Sarepta rebounds on data for limb-girdle muscular dystrophy gene therapy

https://pharmaphorum.com/news/sarepta-rebounds-on-data-for-limb-girdle-muscular-dystrophy-gene-therapy/

FDA says no to Sarepta’s golodirsen, blocking bid to expand its Duchenne stable

FDA says no to Sarepta’s golodirsen, blocking bid to expand its Duchenne stable

The FDA has rejected Sarepta Therapeutics’ new Duchenne muscular dystrophy (DMD) Vyondys 53 due to concerns about potential

X

FDA says no to Sarepta’s golodirsen, blocking bid to expand its Duchenne stable

https://pharmaphorum.com/news/fda-says-no-to-sarepta-blocking-bid-to-expand-its-duchenne-stable/

ICER posts damning report on Sarepta’s Duchenne drug Exondys 51

ICER posts damning report on Sarepta’s Duchenne drug Exondys 51

Controversy has dogged Sarepta’s Duchenne muscular dystrophy therapy Exondys 51 since its approval, and it’s not out of

X

ICER posts damning report on Sarepta’s Duchenne drug Exondys 51

https://pharmaphorum.com/news/icer-posts-damning-report-on-sareptas-duchenne-drug-exondys-51/

Sarepta DMD gene therapy could improve patients’ motor function

Sarepta DMD gene therapy could improve patients’ motor function

Sarepta Therapeutics announced potentially game-changing results from its Duchenne muscular dystrophy gene therapy candidate, with a small phase

X

Sarepta DMD gene therapy could improve patients’ motor function

https://pharmaphorum.com/news/sarepta-dmd-gene-therapy-could-improve-patients-motor-function/

Sarepta dives deeper into gene therapy

Sarepta Therapeutics has handed $30 million to Lacerta in exchange for a group of gene therapies, including a

X

Sarepta dives deeper into gene therapy

https://pharmaphorum.com/news/sarepta-dives-deeper-gene-therapy/

Summit shares plunge nearly 80% after DMD drug fails

Summit shares plunge nearly 80% after DMD drug fails

Summit Therapeutics has axed development of its Duchenne muscular dystrophy drug ezutromid after a spectacular failure in phase

X

Summit shares plunge nearly 80% after DMD drug fails

https://pharmaphorum.com/news/summit-shares-plunge-dmd-drug-fail/

Pharma collaborates to improve chances of NICE backing Duchenne drugs

Pharma collaborates to improve chances of NICE backing Duchenne drugs

Project will initially focus on DMD but could benefit other rare diseases

X

Pharma collaborates to improve chances of NICE backing Duchenne drugs

https://pharmaphorum.com/news/pharmas-join-improve-duchenne-muscular-dystrophy/

1 2 3

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com